Citius Oncology, Inc.(CTOR)

Medical - Pharmaceuticals · Cranford, NY

$0.87-0.08 (-8.05%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T10:46:04.925Z.

Stored calculation inputs

Calculation as of: 2026-10-06T10:46:04.925Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -45,000,450
Quote market capitalization: 81,219,082
Total debt · period ending 2026-06-30: 10,210,272
Cash · period ending 2026-06-30: 16,563,704

FMP input reference: e47236677832b0178bb4e4de0ecbdefb2e069a6eb9feaf5a3a870b06349bdf9c

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CTOR EBITDA Yield Metrics

EBITDA YIELD

N/A

CTOR Competitors' EBITDA Yield

CTOR

Citius Oncology, Inc.

Current

Market Cap

$81.22M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNXU

Conexeu Sciences Inc.

vs CTOR

Market Cap

$83.49M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CGTX

Cognition Therapeutics, Inc.

vs CTOR

Market Cap

$83.96M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ATRA

Atara Biotherapeutics, Inc.

vs CTOR

Market Cap

$84.70M

EBITDA Yield

N/A

TTM Avg

17.90%

3Y Avg

17.90%

5Y Avg

17.90%

ACRV

Acrivon Therapeutics, Inc. Common Stock

vs CTOR

Market Cap

$84.75M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CCLD

CareCloud, Inc.

vs CTOR

Market Cap

$86.69M

EBITDA Yield

21.60%

TTM Avg

23.06%

3Y Avg

41.09%

5Y Avg

38.38%

CRDF

Cardiff Oncology, Inc.

vs CTOR

Market Cap

$87.86M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CSBR

Champions Oncology, Inc.

vs CTOR

Market Cap

$69.05M

EBITDA Yield

0.38%

TTM Avg

3.41%

3Y Avg

4.41%

5Y Avg

3.27%

BMEA

Biomea Fusion, Inc.

vs CTOR

Market Cap

$93.99M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs CTOR

Market Cap

$67.11M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Citius Oncology, Inc. (CTOR)	$81.22M	N/A	N/A	N/A	N/A
Conexeu Sciences Inc. (CNXU)vs ›	$83.49M	N/A	N/A	N/A	N/A
Cognition Therapeutics, Inc. (CGTX)vs ›	$83.96M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$84.70M	N/A	17.90%	17.90%	17.90%
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$84.75M	N/A	N/A	N/A	N/A
CareCloud, Inc. (CCLD)vs ›	$86.69M	21.60%	23.06%	41.09%	38.38%
Cardiff Oncology, Inc. (CRDF)vs ›	$87.86M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.05M	0.38%	3.41%	4.41%	3.27%
Biomea Fusion, Inc. (BMEA)vs ›	$93.99M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$67.11M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CTOR EBITDA Yield Metrics

CTOR Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics